Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07155174 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

A Phase 2 study of Small-cell Lung Cancer, sponsored by AbbVie.

Recruiting
Registry status
Phase 2
Development phase
180
Enrollment target
16
Study locations

NCT07155174: Recruiting Phase 2 study of Small-cell Lung Cancer, sponsored by AbbVie.

NCT07155174 is a Phase 2 study of Small-cell Lung Cancer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 180 participants, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (22% lower). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07155174, a Phase 2 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 2
Development phase
180 participants
Enrollment target
16
Study locations

Study Summary

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide. In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Primary Outcome

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Conditions Studied

Small-cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Atezolizumab
  • DRUG Etoposide
  • DRUG ABBV-706

Study Locations (16)

Other

  • Rambam Health Care Campus- Haifa /ID# 276663 - Haifa
  • Hadassah Medical Center-Hebrew University /ID# 276662 - Jerusalem
  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 277267 - Kaohsiung City
  • Taipei Veterans General Hospital /ID# 277263 - Taipei

Tokyo

  • Tokyo Metropolitan Komagome Hospital /ID# 277335 - Bunkyo Ku
  • National Cancer Center Hospital /ID# 277237 - Chuo-Ku

Connecticut

  • Yale University School of Medicine /ID# 278181 - New Haven

Florida

  • Ocala Oncology Center /ID# 278269 - Ocala

Indiana

  • Fort Wayne Medical Oncology And Hematology /ID# 277336 - Fort Wayne

Ohio

  • University Hospitals Cleveland Medical Center /ID# 277556 - Cleveland

Texas

  • The University of Texas MD Anderson Cancer Center /ID# 277929 - Houston

Central District

  • Meir Medical Center /ID# 277292 - Kfar Saba

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2025-11-25
Est. Completion 2031-09
Phase Phase 2
AbbVie

526 total trials

What NCT07155174 shows while recruiting

NCT07155174 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (22% lower).

The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT07155174 lists 16 locations in 12 states (Other, Tokyo, Connecticut).

Frequently Asked Questions

What is clinical trial NCT07155174 about?

NCT07155174 is a clinical study titled "A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer". Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-70...

What is the current status of trial NCT07155174?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-11-25. Estimated completion is 2031-09.

What conditions does trial NCT07155174 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer.

What interventions are being tested in trial NCT07155174?

The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Etoposide (DRUG), ABBV-706 (DRUG).

Who is sponsoring clinical trial NCT07155174?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07155174 being conducted?

This trial has 16 study locations across Connecticut, Florida, Indiana, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07155174's enrollment target sits among peer trials

180 29th of 79 higher than 51 of 79 other Small-cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07155174

Source: ClinicalTrials.gov NCT07155174, the US trial registry maintained by the National Library of Medicine. NCT07155174 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.